Episode Summary
In this episode of ‘Conversations in Lung Cancer Research,’ host Dr. Rebecca Tay and fellow oncologists A/Prof Surein Arulananda and Dr. Dasantha Jayamanne (DJ) delve into the latest advances in small cell lung cancer treatment.
They explore new first-line treatments, including checkpoint inhibitors and emerging novel agents like lurbinectedin and tarlatamab, highlighting their mechanisms, survival benefits, and toxicity management. The panel also discusses the evolving role of radiotherapy and future directions involving precision medicine and biomarkers. This comprehensive discussion aims to inform clinicians and healthcare professionals about the promising advancements reshaping the small cell lung cancer treatment landscape.
Sponsor
This episode is sponsored by Roche.
TOGA’s SCLC Masterclass
TOGA’s SCLC Masterclass will take place 20 March 2026, at Novotel on Collins, Melbourne.
An advanced workshop covering evolving standards of care and new therapies in SCLC.
Early bird tickets available until 16 Feb 2026.
Show Guests
- Dr Rebecca Tay, Medical Oncologist, Royal Hobart Hospital / Icon Cancer Centre and TOGA Scientific Committee SCLC/Mesothelioma Co-Chair
- Dr Dasantha Jayamanne, Radiation Oncologist, Royal North Shore Hospital and Genesis Care
- A/Prof Surein Arulananda, Deputy Director, Medical Oncology, Thoracic Oncology Trials Lead, Monash Health, Adjunct Associate Professor, Monash University, Basic and Translational Science Committee Member, IASLC
